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Abstract
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder resulting
from expansion of CAG repeats in the Huntingtin (HTT) gene. Previous studies have shown
mutantHTT can alter expression of genes associated with dysregulated epigenetic modifica-
tions. One of the most widely studied chromatin modifications is trimethylated lysine 4 of his-
tone 3 (H3K4me3). Here, we conducted the first comprehensive study of H3K4me3 ChIP-
sequencing in neuronal chromatin from the prefrontal cortex of six HD cases and six non-neu-
rologic controls, and its association with gene expression measured by RNA-sequencing. We
detected 2,830 differentially enriched H3K4me3 peaks between HD and controls, with 55% of
them down-regulated in HD. Although H3K4me3 signals are expected to be associated with
mRNA levels, we found an unexpected discordance between altered H3K4me3 peaks and
mRNA levels. Gene ontology (GO) term enrichment analysis of the genes with differential
H3K4me3 peaks, revealed statistically significantly enriched GO terms only in the genes with
down-regulated signals in HD. The most frequently implicated biological process terms are
organ morphogenesis and positive regulation of gene expression. More than 9,000
H3K4me3 peaks were located not near any recognized transcription start sites and approxi-
mately 36% of these “distal” peaks co-localized to known enhancer sites. Six transcription fac-
tors and chromatin remodelers are differentially enriched in HDH3K4me3 distal peaks,
including EZH2 and SUZ12, two core subunits of the polycomb repressive complex 2
(PRC2). Moreover, PRC2 repressive state was significantly depleted in HD-enriched peaks,
suggesting the epigenetic role of PRC2 inhibition associated with up-regulated H3K4me3 in
Huntington’s disease. In summary, our study provides new insights into transcriptional dysre-
gulation of Huntington’s disease by analyzing the differentiation of H3K4me3 enrichment.
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Introduction
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder character-
ized by abnormal involuntary choreiform movements, cognitive impairment, and psychiatric
dysfunction [1,2]. Neuropathologically, HD patients exhibit neuronal cell loss and gliosis, pri-
marily in the striatum, but also involving the cerebral cortex and other brain regions [3,4].
Although there are currently no effective treatments for persons afflicted with HD, recent trials
of creatine monohydrate among asymptomatic HD gene carriers suggest it may have potential
to delay the disease onset [5]. The cause of HD is an expansion in the number of CAG trinucle-
otide repeats in the coding region of exon 1 of the Huntingtin (HTT) gene [6]. In comparison
to the normal HTT allele, which ranges from 8 to 35 triplet repeats, mutant HTT (mHTT) con-
tains 36 or more repeats resulting in an expanded polyglutamine tract [6]. Repeats between 36
and 39 units show reduced penetrance [7,8].
The toxicmHTT expansion induces numerous and widespread aberrant molecular effects.
Transcriptional dysregulation has been proposed to be a central component of HD pathogene-
sis [9,10]. Altered gene expression has been reported [11] and several studies support alter-
ations at one or more of the stages of RNA processing, translation, protein post-translational
modification and trafficking [12–14]. Previous studies show that mHTT protein physically
binds CREB-binding protein (CBP) and blocks both CBP’s transcription coactivator function
in human and mice [15] and its histone acetyltransferase activity in Drosophila [16]. Studies in
mouse models of HD further illustrate that transcriptional dysfunction is associated with his-
tone hypoacetylation [17,18]. Elevated expression of ERG-associated protein with SET domain
(ESET) in HD patients and in the R6/2 transgenic mouse model increases abnormal trimethy-
lation of histone H3 lysine 9 (H3K9me3) [19]. The decreased expression of acetylcholine recep-
tor 1 (CHRM1) in HD also affects H3K9me3-mediated chromatin remodeling [20].
Interestingly, the gene expression changes in HD are usually associated with dysregulated epi-
genetic modifications [21–23].
One of the most widely studied histone modifications is trimethylated lysine 4 of histone 3
(H3K4me3) [24,25]. H3K4me3 marks active transcription start sites (TSSs) [26–28] and the
strength of H3K4me3 signal at the promoter is strongly correlated with the expression of the
gene [29,30]. Recently, studies in the R6/2 HD transgenic mouse model revealed that
H3K4me3 may play a critical role in the pathway leading to transcriptional dysregulation in
HD [31]. Our earlier study found that epigenetic changes in theHES4 gene are associated with
reduced H3K4me3 and increased DNAmethylation in its promoter, and showed that these
changes were closely correlated with degeneration in the striatum of HD patients [32]. These
previous findings motivated us to investigate the genome-wide pattern of H3K4me3 in HD. In
the current study, we conducted the first chromatin immunoprecipitation using anti-
H3K4me3 antibody followed by sequencing (ChIP-seq) experiments on NeuN-selected neuro-
nal cell nuclei from post-mortem prefrontal cortical samples for six HD cases and six non-neu-
rologic controls.
Results
H3K4me3 modification enrichment characteristics
We analyzed H3K4me3 enrichment in FACS sorted neuronal nuclei derived from postmortem
prefrontal cortex (BA9) of six HD cases and six non-neurological controls (Table 1). A total of
28,608 H3K4me3 peaks were defined when the filtered peaks called from HD and control sam-
ples were combined (S1 Fig). We found that most peaks (59.2%) were called in all twelve sam-
ples (S2A Fig) and on average 63% of total H3K4me3 ChIP-seq reads were mapped to TSS-
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proximal peaks. These are consistent with our prior data showing that H3K4me3 is enriched in
promoters and similar across different individuals [33–35]. The H3K4me3 signal tends to be
stronger when the peak is called in more samples (S2B Fig).
Most H3K4me3 peaks (n = 18,836, 65.8%) were located proximally (within 1 kb) to a TSS
and most (93.5%) were shared between HD and control, with 6.5% peaks (n = 1,850) unique to
HD or control (Fig 1A). Proximal peaks were positioned with a slight upstream position bias
relative to TSSs, in both control and HD samples (Fig 1B), which was seen for both common
and uniquely defined proximal peaks. The 9,772 distal peaks (>1 kb from TSS) consist of 5,671
(58.0%) are from intragenic regions of annotated genes and 4,102 (42.0%) from intergenic
regions. Both proximal and distal peaks were confidently mapped with strong read depth (Fig
1D).
Among proximal peaks, the distribution of peak widths was bimodal with the two modes
being 350 bp and 1700 bp (Fig 1C). The proximal peaks unique to HD are slightly larger (t-test
p-value = 3.28x10-14) than those unique to controls (400bp versus 300bp respectively). The
mode for distal peaks is 350bp, similar to the mode for the smaller proximal peaks.
Differential H3K4me3 between HD and control
To investigate the transcript specific differences in H3K4me3 signal, we extracted H3K4me3
reads within a 2000 bp window centered around every annotated TSS (referred to as promoters
hereafter) regardless of whether a peak was called within that region or not. This strategy per-
mits an assessment of the relationship of H3K4me3 signal to mRNA-seq abundance (see
Method). As a result, we detected 720 genes with significantly different H3K4me3 level in pro-
moters between HD and control, including 104 genes with significantly higher H3K4me3 sig-
nal in HD and 616 genes with significantly higher H3K4me3 in controls (S3 Table). We also
ran the differential analysis for all 9,772 distal peaks, and detected 209 and 51 distal peaks with
significantly higher H3K4me3 signal in HD and control respectively (S4 Table).
Table 2 lists the 22 genes that have the most differential H3K4me3 signal at the proximal
promoter regions between HD and control (q-value< 1x10-4). Among them 15 genes have
Table 1. Characteristics of human brain samples in the study.
Diagnosis ID* Sex CAG
Repeat
Onset
age
Age at
death
PMI+ Antibody Total
reads
Uniquely mapped
reads
Mappability
(%)
Peaks
HD H0001 M 45 44 55 37.25 H3K4me3 6,134,681 5,206,490 84.90% 27,661
HD H0003 M 43 52 71 20.5 H3K4me3 3,292,319 2,930,762 89.00% 24,955
HD H0008 M 49 28 43 21.3 H3K4me3 6,647,419 5,979,404 90.00% 29,710
HD H0009 M 42 45 68 3.73 H3K4me3 2,817,246 2,540,805 90.20% 29,640
HD H0681 M 42 50 69 19.06 H3K4me3 5,567,462 4,858,701 87.30% 27,732
HD H0601 F 45 unknown 56 19.0 H3K4me3 5,943,156 5,282,199 88.90% 30,647
Control C1 M N/A N/A 55 17 H3K4me3 6,028,542 4,927,721 81.70% 40,150
Control C2 M N/A N/A 63 24.5 H3K4me3 8,356,841 7,519,896 90.00% 30,434
Control C3 M N/A N/A 64 28.21 H3K4me3 13,238,359 11,132,414 84.10% 27,419
Control C4 M N/A N/A 74 12 H3K4me3 3,091,666 2,581,032 83.50% 39,323
Control C5 M N/A N/A 81 8 H3K4me3 10,313,831 7,955,599 77.10% 32,907
Control C6 F N/A N/A 68 7 H3K4me3 8,287,623 5,993,036 72.30% 38,970
Control C7 F N/A N/A 69 40.15 Input 15,875,168 12,246,790 77.10% 1,616
*IDs match those for the HD samples that we published previously [12,36] (Labadorf et al. submitted)
+PMI: postmortem interval.
doi:10.1371/journal.pone.0144398.t001
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lower H3K4me3 in HD cases than in controls.HES4, which we previously reported [32], is the
fourth protein-coding gene in this list. The top gene ALG14 catalyzes asparagine (N)-glycosyla-
tion, which is an essential modification that regulates protein folding and stability.
Proximal H3K4me3 signal is correlated with gene expression
We calculated the correlation between the signal at proximal H3K4me3 peaks and the expres-
sion level of the corresponding genes. Even though we performed both H3K4me3 ChIP-seq
and RNA-seq experiments on brain tissue from the BA9 region of the prefrontal cortex, ChIP-
seq was performed on sorted neuronal nuclei while RNA-seq was performed on brain tissue
homogenate because it is not feasible to sort entire cells. Previously we showed that H3K4me3
levels at promoters were highly correlated with transcription levels of genes across multiple cell
types [37]. We confirmed this pattern in both control and HD cases (Spearman’s correlation
coefficient rho = 0.57, p-value< 2.2e-16, see Fig 2A). In addition, because of the bimodality
seen for both the mRNA expression (S3A Fig) and H3K4me3 level (S3B Fig) for both HD and
control, we subdivided genes into high and low groups by gene expression and H3K4me3 level
respectively. Applying a χ² test, we found that genes with high and low H3K4me3 levels
strongly associate with high and low expression respectively (χ2 p-value< 2.2 × 10−16; see Fig
2B for all samples). This relationship was seen in both controls and HD cases (S3C Fig).
We evaluated whether differentially expressed genes (DEGs) between HD and control also
exhibit differential H3K4me3 levels at their promoters. Most genes are neither differentially
expressed nor have differential H3K4me3 signal at the promoters. Among the 961 DEGs and
the 720 genes with differential H3K4me3 signals, 58 genes were found to have both differential
expression and H3K4me3 (blue dots in Fig 2C). No correlation was found between the fold
Fig 1. H3K4me3 proximal and distal peaks in HD and control. (A) The number of H3K4me3 peaks in HD
and control. 487 proximal peaks were unique to HD samples while 381 were unique to controls. 474 distal
peaks were unique to HD samples and 508 were unique to controls. (B) Histograms of the position of
proximal peaks relative to the TSS in HD and control show a slight enrichment upstream the TSS. Small right
panels show zoomed-in histograms for unique proximal peaks (highlighted in black). (C) Histograms of the
distribution of peak widths for proximal and distal peaks were similar in control and HD samples. Proximal
peaks show a bimodal distribution in peak width not seen in distal peaks. The width distributions of unique
peaks are in black. (D) Peak intensities of proximal (blue) and distal (red) peaks are plotted for HD versus
control.
doi:10.1371/journal.pone.0144398.g001
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change of differential expression and that of differential H3K4me3 (Spearman rho = 0.04, Fig
2C). Out of the 58 genes, 20 showed the same direction of alteration; 18 cases of both decreased
expression and H3K4me3 levels in HD and only two cases of both increased genes and
H3K4me3 in HD. The trend that the majority of the dysregulated genes are down-regulated is
consistent with a previous study in the HDmouse R6/2 model [31]. It is worth noting that the
remaining 38 genes are in the opposite direction; increased gene expression but decreased
H3K4me3 in HD (as listed in Fig 2D). These include calcium-signaling genes (e.g. DSG2,
ANXA2, and ANXA3), as well as protein kinase or kinase receptors (e.g.WEE1, OSMR, and
IL17RB). Interestingly, epigenetic regulators are also found, such as PRDM6 (histone methyl-
transferase) and UHRF1 (which can recruit the DNA methyltransferase DNMT1 to regulate
chromatin structure and gene expression). Several genes involved in neuronal function are
seen. For instance, EGFLAM (gene for the Pikachurin protein) is known to play important role
in the retinal photoreceptor ribbon synapse formation [38], and EPHA2, a kinase receptor,
plays multiple roles in neural development [39,40].
Table 2. Genes that correspond to the top 22 differential proximal H3K4me3 peaks.
Gene symbol Gene type log2(HD/
control)
q-value Gene / Function
ALG14 protein coding 1.028 3.63E-09 UDP-GlcNAc transferase: regulates protein folding and stability
SERTAD4-AS1 Antisense -1.075 1.02E-07 Antisense of SERTAD4: no known function
LRRTM2 protein coding 1.110 1.08E-06 leucine rich repeat transmembrane neuronal 2: development of excitatory synapse in
CNS
CTD-3064M3.4 processed
transcript
-1.091 1.96E-06 N/A
FAM184B protein coding -1.067 2.28E-06 No known function
HES4 protein coding -1.506 1.30E-05 Hairy and enhancer of split 4: protein dimerization & transcription factor binding.
CTB-31O20.8 antisense -1.347 1.43E-05 N/A
TMEM61 protein coding -1.958 1.53E-05 Transmembrane Protein 61: no known function
SNORD118 snoRNA 1.464 2.19E-05 Small Nucleolar RNA, C/D Box 118, predicted to serve as guide RNAs in ribose
methylation of rRNA.
COX7B protein coding 1.294 2.24E-05 Cytochrome C oxidase subunit 7B: Mitochondrial, terminal component of respiratory
chain
RP11-
783K16.10
processed
transcript
-1.007 2.43E-05 N/A
MIR5188 miRNA -1.072 2.84E-05 N/A
RAMP3 protein coding -1.198 3.78E-05 Receptor activity modifying protein 3: transport calcitonin-receptor-like-receptor to
plasma membrane
AC092171.1 lincRNA -1.075 3.88E-05 N/A
RP11-982M15.5 antisense -1.738 3.88E-05 N/A
RP11-44N21.4 processed
transcript
-1.067 3.95E-05 N/A
RP5-1120P11.3 lincRNA -1.126 4.65E-05 N/A
SNORD50B snoRNA 1.310 4.99E-05 Small nucleolar RNA, C/D box 50B, predicted to guide 2´-O-methylation of 28S rRNA
DSG2 protein coding -1.592 6.23E-05 Desmoglein 2, cadherin family member 5: calcium ion binding
SNORD13 snoRNA 1.102 7.15E-05 Small nucleolar RNA, C/D Box 13: no predicted function
PALD1 protein coding -1.190 8.66E-05 Phosphatase domain containing paladin 1: no known function
FLRT3 protein coding 1.033 9.09E-05 Fibronectin leucine rich transmembrane protein 3: receptor signaling protein activity
and protein binding, bridging
Note: N/A means either the protein’s function is uncharacterized or there is no literature found on the function of the gene.
doi:10.1371/journal.pone.0144398.t002
Dysregulation of H3K4me3 in Huntington's Disease
PLOS ONE | DOI:10.1371/journal.pone.0144398 December 4, 2015 5 / 23
GO terms enriched in the genes with proximal H3K4me3 peaks
We computed the enriched GO terms of the genes with 720 proximal differential H3K4me3
signals; 104 up-regulated and 616 down-regulated in HD. We only detected GO terms signifi-
cantly enriched in the 616 genes with lower H3K4me3 signals in HD than in control. The non-
redundant GO terms are shown in Fig 3A. Although the biological process GO terms were
diverse, organ morphogenesis and positive regulation of gene expression were the most fre-
quently implicated terms. The molecular function and cellular component GO terms were
related to transcription and the extracellular matrix.
Fig 2. Gene expression and H3K4me3 signal at promoters. (A) Correlation of H3K4me3 signal at promoters and gene expression in control and HD. X-
axis shows the logarithmic base mean value of normalized expression values CPKM (RNA-seq reads count per kilobase of exon length per millions of total
mapped reads), and Y-axis shows the logarithmic signal density of ChIP-seq reads at proximal promoters (i.e. [-1k, 1k] of TSS). It shows that gene
expression levels are positively correlated with the density of H3K4me3 signal at promoters in both controls and HD, with Spearman correlation rho = 0.57.
(B) Histogram of normalized H3K4me3 signal in all samples. Bars are colored according to the frequency of genes with high (red) and low (blue) expression.
(C) Scatter plot of log2(fold change between HD and control) of H3K4me3 signal at promoter versus gene expression. Genes with differential expression but
not differential H3K4me3 are in green; genes with differential H3K4me3 but not differential expression are in red, and genes with both differential expression
and H3K4me3 are in blue. In total, 58 genes show both differential expression and H3K4me3, where only 20 of them show the same direction of
differentiation between control and HD cases. The remainder (38 of 58) shows a lack of concordance between differential expression and differential
H3K4me3 at promoter. (D) Fold changes of expression (in green) and H3K4me3 (in red) between HD and control for the 38 genes with lack of concordance.
doi:10.1371/journal.pone.0144398.g002
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We also calculated enriched GO terms of the 961 DEGs; 718 up-regulated and 243 down-
regulated in HD. Contrary to the differential H3K4me3 results, all detected 664 GO terms were
those enriched with up-regulated genes; 576 terms in biological processes, 51 terms in molecu-
lar functions and 37 terms in cellular components (S4 Fig).
Interestingly, the GO terms enriched with the genes marked with down-regulated
H3K4me3 signals resembled or overlapped with the GO terms enriched with up-regulated
genes as parent-child relationships in the GO hierarchical structure (Fig 3A, S4 Fig). Except for
iron ion binding (GO:0005506) in molecular function terms, all of the GO terms enriched with
the genes with down-regulated H3K4me3 signals were covered by those enriched with up-reg-
ulated genes.
GO terms enriched with the genes with unique proximal peaks are presented; 381 and 487
peaks in control and HD respectively. As seen in Fig 3B, all GO terms enriched with genes
Fig 3. GO terms enriched with proximal peaks in control and HD. (A)GO terms enriched with genes marked with down-regulated H3K4me3 signals in
HD. The GO terms overlapped with those derived from differentially expressed genes are highlighted in red text, with iron ion binding (in black) representing
the only term not seen in the differentially expressed genes. X-axis shows the negative logarithm FDR values. (B)GO terms enriched with genes marked with
unique proximal peaks in HD (right; orange) and in control (left; green). These terms also overlap with those seen in HD differentially down-regulated genes.
doi:10.1371/journal.pone.0144398.g003
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marked with unique proximal peaks in control overlapped with those for genes marked with
down-regulated peaks in HD (multicellular organismal development (GO:0007275) in Fig 3B
is included in multicellular organismal process (GO:0032501) in Fig 3A). In HD, interestingly
GO terms related to lumen (nuclear lumen (GO:0031981), intracellular organelle lumen
(GO:0070013), and membrane-enclosed lumen (GO:0031974)), were detected. The genes for
which unique HD proximal peaks are found at their TSS, tend to represent nuclear, organelle,
and intracellular components. Among the GO terms for biological processes, homophilic cell
adhesion (GO:0007156) was detected for genes with unique H3K4me3 proximal peaks.
Networks of the genes with differential proximal H3K4me3 peaks
We conducted pathway analysis with the SPIA tool [41] and mapped the genes with differential
H3K4me3 on biological pathways. We detected eleven significant pathways (see S5 Table), and
five of these are signaling pathways (Rap1, PI3K-Akt, cAMP, Hippo, and Calcium). Consistent
with our GO analysis above indicating that many genes with down-regulated H3K4me3 in HD
are enriched in extracellular or membrane GO terms, our pathway analysis found that these
genes tend to be clustered at the cellular membrane and located in the upper ranks in the sig-
naling pathways and the extracellular matrix (ECM)-receptor interaction pathway.
We also calculated the enriched pathways for DEGs. We detected 25 significant pathways
and found that most genes in these pathways were up-regulated in HD (see S6 Table). The
PI3K-Akt and Hippo signaling pathways were also detected to be enriched. As reported by
Labadorf et al. (submitted), many of the pathways were related to immune function.
To investigate the relationships between the genes with differential H3K4me3 and DEGs,
we extracted the gene interaction sub-networks of the detected pathways in S5 and S6 Tables.
The gene interaction annotation used in this analysis is also based on the annotation in KEGG
database. All genes in significant pathways are summarized in S7 Table. As we observed in the
above pathway gene enrichment analysis, the two gene sub-networks of DEGs were extracted
as the immune system module (Fig 4). Each sub-network was composed of a specific gene fam-
ily. One of the two immune system sub-networks was formed by chemokine receptors (CCR1,
5, and 9; CXCR1, 2, and 4) and ligands (CCL2, and 26; CXCL1, 5, 6, and 7), and the other was
formed by complement subcomponents (C1QA, C1QB, C1QC, C1R, and C4B).
On the other hand, the sub-network of the genes with differential H3K4me3 was mainly
detected as the signaling pathway module (Fig 4) and was composed of various signaling genes
listed in S7 Table. Those genes in the signaling pathway module straddled across the cell mem-
brane to the inside of the cell and preserved cascade structures in the pathways detected in the
above pathway gene enrichment analysis. Although several DEGs were also included in the sig-
naling pathway module, those DEGs were in a specific gene family (e.g. immunoglobulin-like
receptor gene family in the upstream of the signaling pathway module) and were not the hubs
in the module. That is, even if we remove the DEGs from the signaling pathway module, still
the hierarchical structure composed of the genes with differential H3K4me3 remains in the
module. We also found the ECM-receptor pathway module composed of 12 extracellular com-
ponent genes such as collagen and laminin.
Evidence for regulatory role of distal H3K4me3 peaks
One third of H3K4me3 peaks were localized at more than 1 kb away from any known TSS. To
investigate their potential regulatory functions, we first assessed whether they overlapped with
genomic regions with other regulatory signals. Recent progress in functional genomics has
amassed many biochemical data for regulatory elements, including the co-occurring histone
marks of H3K4me1 and K3K27ac [26], bidirectional CAGE signal at promoters [42], hotspot
Dysregulation of H3K4me3 in Huntington's Disease
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of transcription factor binding sites [43], clustered DNaseI hypersensitive sites [44], and
enriched eQTLs [45]. By aligning these signals from prefrontal cortex and other cortical related
brain regions with our H3K4me3 data, we found interestingly many of the distal H3K4me3
peaks co-localize with regulatory elements defined by these signals. For example, although the
distal peak in Fig 5A was called in both HD and control samples, it is much stronger in HD. It
harbors eleven SNPs that were shown to be eQTLs in brain (black vertical lines in Fig 5A).
Notably, this region is also centered on ChIP-seq peak of enhancer marks of H3K27ac and
H3K4me1 on human frontal cortex from the Roadmap Epigenomics project. Active enhancers
often correspond to open chromatin regions, which facilitate binding of transcription factors.
Indeed, this region has open chromatin (the DNase track in Fig 5A) and is bound by more
Fig 4. Sub-networks of DEGs and genes with differential H3K4me3. Each node represents a gene; the fill color of each node indicates the fold-change of
gene expression between HD and control, and the outline color of each node indicates the fold-change of H3K4me3 between HD and control. Immune
system and ECM-receptor pathway modules were composed of specific gene families. On the other hand, signaling pathway modules were composed of
various signaling genes forming hierarchical structure. The directions of all the arrows were drawn toward the bottom of figure.
doi:10.1371/journal.pone.0144398.g004
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than 20 transcription factors (ENCODE TFs ChIP-Seq track in Fig 5A) particularly those
known key factors for facilitating the 3D structure of chromatin, such as CTCF [46] and SP1
[47,48]. Finally, CAGE, a technique for capturing the 50 end of mature transcripts, was recently
found useful for identifying active enhancers based on a bi-directional signal [42]. It showed
clear bi-directional signals at this region and an enhancer was predicted by FANTOM5 consor-
tium (CAGE track in Fig 5A). Furthermore, we also found that the role of distal peaks as
enhancers is also supported by the aggregated signal of CAGE tags, H3K4me3, H3K9ac, and
DNase I on all distal peaks (Fig 5B). Transcription directionality based on the CAGE data from
the FANTOM5 project further supports this view (Fig 5C). Thus the distal differential
H3K4me3 peaks may represent differential enrichment at enhancer sites.
By computing the percentage of distal peaks overlapping with three datasets of known
enhancers (see Methods), we found that 15–22% of distal peaks significantly overlapped
known enhancers (p-value< 2.2 × 10−16; Fig 5D). Altogether, an estimated 36% of distal peaks
overlapped with at least one of three enhancer datasets (S4 Table). The aggregation signals of
regulatory marks were even more enriched on this subset of distal peaks than the total set of
distal peaks, as seen from the third column of Fig 5B. From the set of distal peaks that overlap
with at least one of the three known enhancer sets, 74 enhancer-like distal peaks are differen-
tially enriched between HD and control (S4 Table).
To investigate the potential functional roles of distal H3K4me3 peaks, we analyzed the
TFBS enrichment at these peaks with the most recent TF ChIP-seq data from the ENCODE
Fig 5. Overlapped regulatory signals and differentially enriched TF binding on distal peaks. (A) UCSC genome browser of a genomic locus
(coordinate in hg19 shown on the top) where a distal H3K4me3 peak, called in both control and HD cases, overlaps with enhancer regulatory features
including enriched H3K4me1 (“Roadmap H3K4me1”), H3K27ac (“Roadmap H3K27ac”), DNase I (“Roadmap DNase I”), TFs binding hotspot (“ENCODE TFs
ChIP-seq”), and bidirectional CAGE signals (“FANTOMCAGE”). (B) Aggregation plots of several types of regulatory signals, including CAGE (1st row),
histone marks (2nd row), TF binding (3rd row), and DNase I hypersensitivity (4th row), centered on the middle of H3K4me3 peaks. (C) Directionality of
H3K4me3 peaks represented by CAGE tags shows that, unlike the strong bias towards sense strand for proximal peaks, distal peaks show similar level of
CAGE tags in both directions. (D) Fraction of distal peaks overlapping with different sources of known enhancers occurred at rates greater than expected
(All = blue, control = red, HD = green, Expected = grey). (E) Transcription factors binding in differentially enriched distal peaks.
doi:10.1371/journal.pone.0144398.g005
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project (see Methods). We identified those TFs specifically binding to distal peaks that were
differentially enriched between HD and control. By comparing the TF binding occurrences
between 209 and 51 differential distal peaks that were up-regulated in HD and control respec-
tively, we found that six transcription factors (ZBTB7A, E2F6, CCNT2, HMGN3, EZH2, and
SUZ12) had enriched binding sites in HD-specific distal peaks and two TFs (GATA3 and
KAP1) had enriched binding sites in control-specific distal peaks (Fig 5E). Among these,
EZH2, a histone methyltransferase, had the most significant difference (adjusted p-
value = 2.87x10-10).
Both EZH2 and SUZ12 are subunits of polycomb repressive complex 2 (PRC2), which can
primarily methylate histone 3 on lysine 27 (H3K27me3) and therefore repress transcription. In
this study, we further looked into the enrichment of Polycomb-repressed regions (indicated by
the ‘ReprPC’ and ‘ReprPCWk’ ChromHMM states in human frontal cortex of the Roadmap
Epigenomics project [49]) in HD-specific peaks. We found that the repressed Polycomb state,
representing the H3K27me3 signal, is depleted in the distal peak regions with significantly
enriched H3K4me3 signal in HD (hypergeometric test p-value = 4.66x10-5), but not in control-
enriched distal peaks (hypergeometric test p-value = 0.39). Previous study had shown that
H3K4me3 can inhibit the activity of PRC2 in an allosteric fashion assisted by the Su(z)12 C ter-
minus [50]. Our result of PRC2 depletion in the regions with increased H3K4me3 in HD might
suggest that the epigenetic role of PRC2 inhibition is caused by up-regulated H3K4me3 in
Huntington’s disease.
Discussion
While patterns of H3K4me3 have been previously studied in the R6/2 mouse model of HD
[31], we believe this is the first genome wide study of this mark in human HD versus control
brains. We had previously performed mRNA-sequencing in a series of 20 HD and 49 non-neu-
rological control brains, and therefore, we were able to compare the patterns of H3K4me3
enrichment with 961 differentially expressed mRNAs (FDR q<0.01) in HD and control brains
(Labadorf et al. submitted). Because 50% to 90% of neurons have degenerated in the HD stria-
tum, even among low-grade HD cases [3], we chose to analyze the prefrontal cortex (Brod-
mann area 9). While the hallmarks of HD pathology (e.g. intranuclear inclusion bodies) are
present in the prefrontal cortex, the extent of neuronal degeneration is considerably less severe
than that seen in the striatum [3,51]. Some of the HD samples studied here have been previ-
ously studied by microRNA-sequencing and mRNA-sequencing of the same region of the pre-
frontal cortex [12,36] (Labadorf et al. submitted).
In this study, we sought to minimize the biases introduced by simple neurodegeneration
in two ways. First, the H3K4me3 ChIP-sequencing was performed in NeuN+ sorted neuronal
nuclei [35,52]. Thus, the contrast is specific to neurons in both HD and controls and
accounts for possible differences in the densities of specific cell types in the HD brain due to
degeneration or reactive gliosis. Second, the prefrontal cortex (BA9), a region with mild
neuropathological involvement in HD [3,4], was selected for analysis. A total of 28,608
H3K4me3 peaks were defined in the combined HD and control samples. While most peaks
(93.5%) were called in both HD and control brains and a majority (59.2%) were called in all
twelve samples studied, 961 were uniquely called in HD brain and 889 were uniquely called
in controls (Fig 1, S2A Fig). The H3K4me3 mark is known to mark active transcription start
sites (TSS), and 65.8% of the called peaks were located within 1,000 bp of an annotated TSS
(designated “proximal peaks”). Both the proximal peaks and distal peaks (positioned at
greater than 1000 bp of an annotated TSS) were robustly called with confident read depths
(Fig 1D).
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In the differential analysis of H3K4me3 peaks, 720 proximal peaks were differentially
enriched, and these were primarily down-regulated among HD cases relative to controls (104
up-regulated and 616 down-regulated in HD). In contrast, 260 distal peaks were differentially
enriched, and these were primarily up-regulated in HD relative to controls (209 up-regulated
and 51 down-regulated in HD). These findings suggest that proximal and distal H3K4me3
peaks perform different functions and respond differently to the pathology initiated by the
mutant HTT protein.
The H3K4me3 mark is known to associate with active gene transcription, and this relation-
ship is confirmed in this study, where high versus low H3K4me3 proximal peak density and
was strongly related to high versus low mRNA expression (Fig 2B, χ2 p-value < 2.2 × 10−16). It
should be noted however, that for the 720+961 “differential” genes, the rho for both HD and
controls is reduced, although more in HD (Spearman rho = 0.33) than in controls (rho = 0.4).
In contrast however, differentially enriched H3K4me3 proximal peaks were not associated
with increased expression of the implicated genes. Few genes with differential enrichment of
H3K4me3 density showed differential mRNA levels. The disruption of the regulatory influence
of the H3K4me3 enrichment on gene expression in HD brains provides strong evidence for
transcriptional dysregulation as a major component in disease expression in HD (see Fig 2B
and 2C), as has been previously proposed [9,10], or it may suggest that additional epigenetic
marks or mechanisms are required to better explain the full range of transcriptional dysregula-
tion associated with the disease [53].
The genes with the most differentially enriched H3K4me3 marks at their TSS are ALG14
(Asparagine (N) glycosylation) which regulates protein folding and stability; LRRTM2 (leucine
rich repeat transmembrane neuronal 2), involved in development of excitatory synapses;HES4
(Hairy And Enhancer Of Split 4) which is involved in protein dimerization and transcription
factor binding; and COX7B (Cytochrome C Oxidase Subunit 7B) which is a terminal compo-
nent of the mitochondrial respiratory chain. Of these only HES4 is differentially expressed, and
we have previously described HES4 as having differential H3K4me3 enrichment and being
related to the extent of pathological involvement in the striatum [32].
Other genes shown to have a reduced H3K4me3 signal in HD or corresponding mouse
model from a previous study [31] are also revealed in this study. For instance, the down-regu-
lated Bdnf gene has reduced H3K4me3 signal at one of its promoters (exon II) in HD and R6/2
mouse. We also observed the same trend (fold change = 0.78, q-value = 0.027). Other genes
shown have significant decreases of H3K4me3 in Vashishtha et al. also had decreased
H3K4me3 levels in our results, such as PENK1 (fold change = 0.34, but not significant), and
DRD2 (fold change = 0.43, q-value = 0.029).
Differential H3K4me3 enrichment is not associated with differential gene
expression
While a genome wide analysis of mRNA levels from our sequencing studies showed a strong
correspondence with H3K4me3 enrichment (χ2 p-value< 2.2 × 10−16; see Fig 2B), this rela-
tionship was notably absent for differentially enriched H3K4me3 peaks and differentially
expressed genes (DEGs) (see Fig 2C). Notably, 718 (74.7%) of the 961 DEGs are up regulated
in HD, suggesting that one might expect to see an increase in differential H3K4me3 enrich-
ment at the TSS of these DEGs. However, only 58 of the 720 differential H3K4me3 proximal
peaks are associated with DEGs, and only 20 of these (2.8% of the 720) are in the expected reg-
ulatory direction (18 down-regulated DEGs have reduced differential H3K4me3, and 2 up-reg-
ulated DEGs have increased differential H3K4me3 enrichment), suggesting that differential
H3K4me3 is not responsible for the DEGs. This result holds with a previous study [31] where
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genome-wide analysis of H3K4me3 and RNAseq in the 12-week cortex of R6/2 mouse revealed
a high degree of overlap between genes with decreased expression and decreased H3K4me3 lev-
els (e.g. 293 in down:down, 24 in up:up). Although the mouse data may not be directly compa-
rable, by simply checking the orthologs of the 293 down:down genes in our human data we
found that most of these genes also have a down:down relationship (i.e. decreased H3K4me3
levels and decreased expression in HD). While both studies found consistent results for the
selected genes and there is a large overlap between genes with same direction change in expres-
sion and H3K4me3 levels, nonetheless, a proportion of genes were found not infrequently and
unexpectedly in opposite directions in both studies. This discordant pattern holds up in an
examination of the concordance of the GO enriched terms for down-regulated DEGs overlap
with increased differential H3K4me3 signals described below.
Analysis of GO term enrichment for genes at enriched H3K4me3 peaks
In an analysis of GO term enrichment only the genes associated with down-regulated peaks in
HD showed significant GO terms, with a total of 166 enriched GO terms. We compared the
GO terms for differential H3K4me3 with those for the 961 differentially expressed mRNAs
(q<0.01). In GO and pathway analysis, we observed similar GO term enrichment in the up-
regulated mRNA genes in HD and the down-regulated H3K4me3 target genes in HD.
Although the biological processes of these terms were diverse, organ morphogenesis and
positive regulation of gene expression were the most frequently implicated terms. Common
molecular function and cellular component GO terms relating to transcription (e.g. Sequence
specific DNA binding and RNA pol II activity) and the extracellular matrix (membrane and
cell periphery) were observed (see Fig 3). The unexpected pattern of opposite trend of regula-
tion (e.g. increased mRNA levels with decreased H3K4me3) presenting overlapping GO term
enrichment, suggests the increased levels of mRNA are likely attributed to regulatory mecha-
nisms other than H3K4me3 control of transcriptional initiation.
Transcriptional dysregulation has a crucial role in HD pathology. Interactions between
mutant HTT and important TFs including SP1 [54–56], REST [54,57,58], TAFII130 [56] and
others have been observed and may contribute to the observed transcriptional dysregulation
[9,59]. Transcriptional dysregulation may also be influenced by the accumulation of the
mutant HTT protein. Two recent studies with in vivo and HD Drosophila models showed that
the mutant HTT protein facilitates the chromatin regulator PRC2 and alters H3K4me3 states
at transcriptionally active genomic loci [60,61].
Several mechanisms might be responsible for the disparity between H3K4me3 enrichment
and mRNA levels. Our findings of decreased histone modifications may represent an attempt
by the neuron to rescue or reverse via epigenetic means, the aberrant increase in transcription
that we see in mRNA levels by RNA-sequencing. Alternatively, decreased H3K4me3 signal has
been associated with apoptosis [62] which has been strongly implicated in HD and thus the dif-
ferences that we observe may represent part of that neurodegenerative process in HD.
Role of distal H3K4me3 peaks
We subdivided the peaks into proximal (defined as within 1000bp of a transcription start site),
and distal peaks (located greater than 1000bp of a transcription start site. One third of
H3K4me3 peaks (34.2%) were located distally from transcription start sites, and 260 of them
were differentially enriched between HD and control (S4 Table) with 209 up-regulated and 51
down-regulated in HD.
H3K4me3 is usually considered as a promoter mark for actively transcribed genes [26,63–
65]. However, several studies support that H3K4me3 can mark enhancers as well [66,67]. In
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this study we projected the commonly known regulatory marks on H3K4me3 peaks and found
that the distal peaks show largely similar patterns of aggregation as proximal peaks, as seen in
Fig 5B. One possibility is that some distal peaks are promoters of unannotated genes or non-
coding RNAs [68,69]. But this explanation does not appear to account for most distal peaks for
the following reasons: First, if the distal H3K4me3 signal is an active promoter for an unanno-
tated gene, one may expect a corresponding increase RNA-seq reads derived from the tran-
scription at that position. However, most distal peaks have very low RNA-seq read coverage (0
or 1 read, see S5 Fig). Second, in our CAGE tag directionality analysis, distal peaks show a clear
pattern of bidirectionality, unlike the uni-directionality for proximal peaks. This finding is con-
sistent with the defining feature of transcribed enhancers (or eRNAs) recently characterized by
the FANTOM consortium [42]. By intersecting distal peaks with three known sets of enhanc-
ers, an estimated 36% of the distal H3K4me3 peaks appear to localize to enhancer sites.
It is worth noting that the distal peaks are generally less intensive than proximal peaks (Fig
1D). Although we had previously checked the specificity of the anti-H3K4me3 antibody we
used, for absence of detectable immunoreactivity for the related epitopes of H3K4me2 and
H3K4me1 [70], future studies are needed to explore whether the antibody detects other types
of histone modification at distal peaks.
TF differentially bound in distal peaks
We compared the TFs bound at the proximal and distal peaks, and found that the TFs associ-
ated with chromatin structuring are enriched in distal peaks. Chromatin looping allows far-dis-
tant enhancers to be brought into the proximity of promoters of protein-coding genes.
Enhancers are thought to interact with protein complexes necessary for chromosome looping
and to facilitate RNA Polymerase II recruitment of the promoter of the target gene. This result
is consistent with the finding from a recent study using ChIA-PET interaction data that cohe-
sin, CTCF, and ZNF143 are the key components of 3D chromatin structure [71]. Studies in
peripheral tissues found that many of the ectopic H3K4me3 sites corresponded to enhancers
bound by CTCF and cohesin [66,67]. Recently the link between distal H3K4me3 peaks and
promoter-enhancer loopings has also been reported for human cerebral cortex [72,73].
When looking at the enriched TFs in differentially enriched H3K4me3 peaks between HD
and control, we found six transcription factors have enriched binding sites in HD-specific dis-
tal peaks, including EZH2 and SUZ12. Previous studies also found the role of EZH2 for DNA
hypermethylation in the epigenetic inhibition of the dopamine receptor D4 (DRD4), which is
important for neurodegenerative disease such as HD and Parkinson’s disease [74]. These find-
ings may implicate the enrichment of EZH2 in the HD-specific distal H3K4me3 peaks.
EZH2 and SUZ12 are also core subunits of the polycomb repressive complex 2 (PRC2).
Given that PRC2 should recognize the mark that EZH2 generates, the finding that PRC2 is
depleted while EZH2 is enriched suggests that the H3K4me3 mark may appear preferentially
on those EZH2 target regions that are not regular targets of the PRC2 complex.
H3K4me3 was recently found to inhibit PRC2 assisted by the Su(z)12 C terminus [50]. Our
findings of depleted PRC2 in HD-enriched H3k4me3 peak regions may indicate that increased
H3K4me3 in HD is associated with PRC2 inhibition.
In summary, we examined the differential enrichment of H3K4me3 signals and the relation-
ship of this histone mark to RNA levels in both HD and control prefrontal cortex. Genes with
differential H3K4me3 signal at their promoters were rarely found to be differentially expressed.
These findings support the hypothesis that transcriptional dysregulation plays an important
role in the pathogenesis of HD. GO term analysis of the genes with differential H3K4me3
enrichment identified terms only among the set of genes with down-regulated H3K4me3 in
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HD, and most frequently implicated biological process terms with organ morphogenesis and
positive regulation of gene expression. More than 9000 H3K4me3 peaks were located not near
to any recognized transcription start sites and approximately 36% of these “distal” peaks co-
localized to known enhancer sites. Transcription factors enriched in distal peaks, implicated
the polycomb repressive complex 2 (PRC2), suggesting that H3K4me3 histone hypermethyla-
tion is linked to dysregulated polycomb activity in the HD neuronal epigenome.
Materials and Methods
H3K4me3 ChIP-seq sample preparation
Postmortem brain tissues from the prefrontal cortex Brodmann area 9 (BA9) were obtained
from the Harvard Brain and Tissue Resource Center (HBTRC), McLean Hospital, Belmont
MA. Six human HD post-mortem samples were selected for ChIP-seq. HD cases were con-
firmed to have expanded CAG repeats longer than 40 (mean = 44.3), a mean age at death of
60.3 years, and a mean postmortem interval of 20.1 hours. Six non-neurological controls of
similar age (mean = 67.7), sex, and postmortem interval (mean = 19.6) were selected from sam-
ples studied previously in the Akbarian Lab [33–35] for H3K4me3 ChIP-sequencing (Table 1).
This study has been designated exempt (Protocol # H-28974) by the Boston University School
of Medicine Institutional Review Board, as no human subjects were studied and all data are
derived from post-mortem human brain specimens.
Neuronal nuclei from prefrontal cortex BA9 were NeuN+ labeled and fluorescence acti-
vated sorted (FACS) for subsequent H3K4me3 ChIP-seq. Briefly, approximately 300 mg to
500 mg of -80°C frozen grey matter dissected from BA9 was homogenized in 5 ml lysis
buffer and ultracentrifuged over sucrose solution at 24,400 rpm for two hours at 4°C. The
resulting pellet was suspended in 550 μl PBS, and immunolabeled with NeuN for 60 minutes
while rotated in darkness. NeuN+ and NeuN- fractions were separated and collected by
FACS [52].
ChIP sequencing was performed for the NeuN+ fraction. Briefly, genomic regions with
H3K4me3 modification were extracted by chromatin immunoprecipitation by incubating
digested nuclei with anti-H3K4me3 (Upstate; cat # 07–473) at 4°C overnight and further pre-
pared into ChIP-seq library for sequencing, as described previously [75]. For each brain sam-
ple, 1 μg of DNA was used to construct sequencing libraries using Illumina TruSeq Sample
Prep Kit, according to the manufacturer’s protocol (Illumina, San Diego, CA), and sequenced
using 51nt single-end reads on Illumina’s GA II. The ChIP-seq data for six Huntington’s dis-
ease patients and six controls from this study have been submitted to GEO (http://www.ncbi.
nlm.nih.gov/geo/) under the accession number of GSE68952.
H3K4me3 ChIP-seq read mapping and peak detection
Wemapped all reads in H3K4me3 ChIP-seq libraries to the human reference genome (hg19)
with Bowtie (version 1.0.0) [76] allowing 1 mismatch (see Table 1 for mapping statistics).
Mapped reads were used for the input of the MACS algorithm (version 1.4.0rc2) [77] to iden-
tify regions in the genome that are enriched in H3K4me3 (called H3K4me3 peaks or peaks in
short). We extracted H3K4me3 peaks with false discovery rate (FDR) 0.01. Peaks that were
called in fewer than half the HD samples or fewer than half the controls were removed from
that group respectively. We then merged the remaining peaks from each group to create a
union set of peaks for all subsequent analyses. Thus some peaks were called in only the HD
group, while others were called only among controls.
The union set of peaks were designated as “proximal” if the distance between the central
points of peaks to the nearest transcription start site (TSS) of a gene is less than or equal to
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1 kb, otherwise they were designated as “distal” peaks. We further annotated the peaks as
either “common” or “unique” based upon the fold change of H3K4me3 signal at the peak
summit between HD and control: common peaks have less than or equal to 2 fold change,
and unique peaks have greater than 2 fold change. We defined the H3K4me3 signal at a
peak by first taking the average of the RPM (reads per million) at the summit position over
samples in HD and control, then normalizing the peak signals across the HD and control
groups based on the “invariant set” method [78] (see S1 Table for summary of detected
peaks).
RNA-seq data
Analyses reporting differential expression of mRNA in HD versus controls are reported else-
where (Labadorf et al. submitted). DESeq2 [79] was used to identify differentially expressed
genes (DEGs) between HD and control, adjusting for age at death binned into intervals 0–45,
46–60, 61–75, and 90+ and a categorical RNA Integrity Number (RIN>7 and RIN7) as
covariates. Differential expression analysis identified 961 out of 27,907 confidently expressed
genes with significantly altered expression at q-values 0.01 and abs[log2(fold change)] 1 in
20 HD vs. 49 control samples from the BA9 region of the prefrontal cortex. The list of all 961
DEGs is in S2 Table. Sample information is provided in Table 1 and the methods to define
DEGs are found in (Labadorf et al. submitted).
To correlate gene expression with H3K4me3 signal at promoters, we extracted the normal-
ized counts from DESeq2 (e.g. counts(dds, normalized = TRUE)) and further normalized the
values by the total length of meta-exons of annotated genes. Meta-exon were defined by merg-
ing all overlapping exons of a gene.
Detection of differentially enriched H3K4me3 peaks
We extracted ChIP-seq reads mapped to the promoter regions (defined as ±1000 bp of TSS)
for all annotated transcripts (Gencode v17) [80] using the coverageBed tool in bedtools (ver-
sion 2.19.0) [81]. We then applied the DESeq2 algorithm (version 1.4.5) [79] to detect tran-
scripts with differential H3K4me3 signals at promoters between HD and control (q-
value 0.01 and abs[log2(fold change)] 1). For genes with multiple expressed transcripts,
we selected the transcript with the lowest q-value from the DESeq2 result for subsequent analy-
ses, in order to match with the differentially expressed genes from RNA-seq. A list of 720 genes
with differential H3K4me3 proximal peaks is in S3 Table.
For distal peaks, we extracted the total reads mapped to each peak across all samples and
used DESeq2 to compute enrichment of H3K4me3 signal between HD and control. Using the
same cutoff as for promoters, we defined 260 distal peaks with significant enrichment and this
list is in S4 Table.
Gene ontology analysis
Using GOseq (version 1.16.2) [82], we identified significantly enriched gene ontology (GO)
terms for the following sets of genes: (1) the genes that correspond to the proximal differential
H3K4me3 peaks and (2) the nearest genes to the unique proximal peaks. To compare these
results with differentially expressed genes between HD and control, we also computed the GO
term enrichment (q-value 0.01) for the 961 DEGs (Labadorf et al. submitted). We used
REVIGO web server [83] to summarize and reduce the complexity of the significant GO terms
(simRel score cutoff = 0.7).
Dysregulation of H3K4me3 in Huntington's Disease
PLOS ONE | DOI:10.1371/journal.pone.0144398 December 4, 2015 16 / 23
Pathway analysis
We identified significantly enriched pathways with SPIA (version 2.16.0) [41] for the genes
that corresponded to the proximal differential H3K4me3 peaks. We then extracted the sub-
pathways containing the genes with KEGGgraph [84]. We also applied the same analysis to the
set of 961 DEGs (Labadorf et al. submitted).
Transcription factor enrichment in H3K4me3 peaks
Transcription factor (TF) binding regions were extracted from the TFBS cluster file (wgEnco-
deRegTfbsClusteredV3) downloaded from the UCSC genome browser [85], which correspond
to peaks called from ChIP-seq data for 161 TFs in 91 cell types performed by the ENCODE
consortium [86,87]. We then intersected the H3K4me3 peaks with the TF binding regions and
determined the number of TFs found in each category of H3K4me3 peak. Each overlapping TF
was counted only once, regardless of the number of different cell types in which it was found.
We then compared the number of occurrences of TFs between the two categories of H3K4me3
peak by Fisher’s exact test, and corrected the resulting p-values for multiple testing using the
Benjamini-Hochberg procedure. Odds ratios (OR) were estimated from Fisher’s exact test. TFs
with q-value< 0.01 and odds difference>30% (i.e. OR>1.3 or OR<0.7) were deemed
significant.
Enrichment of other regulatory signals with H3K4me3 peaks
In addition to TF binding data from the ENCODE consortium, we also compared our
H3K4me3 peaks with the regulatory signals from the following three sources: (1) CAGE signal
in the frontal lobe adult brain from the FANTOM5 project [42], (2) H3K4me1, H3K4me3,
H3K27ac, and H3K9ac ChIP-seq signal in the middle frontal lobe of brain, and (3) DNase I sig-
nal in human fetal brain downloaded from the Roadmap Epigenomics project [49]. For each
H3K4me3 peak, we first extended to 1000bp in length centered at the maximum value of over-
lapped DNase narrowPeak (if any) or the midpoint of the H3K4me3 peak. Then we subdivided
each peak into 200 bins (i.e. 5bp per bin) and computed the mean values of the signal in each
bin, which were then used to create the aggregation plots in Fig 5B. The transcription direction-
ality (in Fig 5C) of each peak was computed using the same definition as that used in the FAN-
TOM5 project [42]. Briefly, the normalized CAGE signals from first half bins (i.e. 1–100 bins)
and second half bins (101–200 bins) were used to calculate a peak-set wide directionality score,
D, for each peak over aggregated normalized reverse, R, and forward, F, strand CAGE signals
across all peaks, D = (F-R) / (F+R).
To investigate whether our distal H3K4me3 peaks may function as enhancers, we compared
them with three sets of enhancer annotations: (1) the ‘strong’, ‘weak’, or ‘bivalent’ enhancers
based on genome-wide chromatin states of the brain dorsolateral prefrontal cortex tissue gen-
erated by the Roadmap Epigenomics consortium [49], (2) the super enhancers in brain mid-
frontal lobe defined by occupancy of the master transcription factors and mediators [88], and
(3) the transcribed enhancers defined based on the bidirectional CAGE signal from the FAN-
TOM5 project [42].
Supporting Information
S1 Fig. Flowchart of H3K4me3 peak calling. This figure depicts the process by which the
ChIP-seq data were aligned and processed to identify proximal and distal peaks, as well as dif-
ferentially expressed common and unique peaks.
(TIF)
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S2 Fig. (A) The number of HD and control samples supporting a called H3K4me3 peak.
Most peaks (59.2%) were called in all six HD and control brains. The area of the bars corre-
sponds to the number of peaks. Only peaks with at least 3 samples supported in either of
the groups are included in this plot and analyzed in this study. (B) The number of samples
supporting a H3K4me3 peak and its normalized signal in each group. Peaks called in all six
HD and all six controls had higher peak densities than did peaks called in fewer than six.
(TIF)
S3 Fig. (A) mRNA levels are bimodal for both HD and control, and consequently we subdi-
vided then into “high” and “low” groups (dotted line). (B) The distributions of both HD
and control H3K4me3 peaks are bimodal and consequently we subdivided them into
“high” and “low” groups. (C) Histogram of H3K4me3 mean normalized signals in HD
cases (left) and controls (right). Bars are colored according to the high (red) or low (blue)
expression level. Both HD and control cases show a similar level of correspondence between
expression and H3K4me3 level.
(TIF)
S4 Fig. GO terms enriched with genes up-regulated in HD. The GO terms overlapped with
those of genes with down-regulated H3K4me3 peaks are highlighted in red.
(TIF)
S5 Fig. The distribution of expression level of distal peaks, measured as the median of
RNA-seq reads summit in the distal peaks across the samples in HD and controls, shows
that most distal peaks are covered with no (0) or low (e.g.<10) RNA-seq reads.
(TIF)
S1 Table. Detected H3K4me3 peaks in control and HD. CT: Control. Distance to TSS: Dis-
tance is measured from the center of each peak to a TSS of the nearest gene. If the peak center
is located upstream (50) of TSS, the distance is minus; otherwise, plus. Location: If a peak over-
laps with any gene in GENCODE v17, it is categorized as intragenic; otherwise, intergenic.
Note that a peak may be located intragenic of a gene, but it may refer to a different gene with
the nearest distance to TSS.
(XLSX)
S2 Table. List of 961 differentially expressed genes. SE: Standard error.
(XLSX)
S3 Table. List of 720 genes with differential H3K4me3 signal in the promoter regions. SE:
Standard error.
(XLSX)
S4 Table. List of 9772 distal peaks. 260 distal peaks with differential H3K4me3 signal are
marked as “Yes” in the DE-H3K4me3 column. 3560 distal peaks overlapping at least one
enhancer sets are marked as “Yes” in the “putative enhancer peak” column. SE: Standard error.
(XLSX)
S5 Table. Pathways enriched with genes with differential H3K4me3 signals. In the link to
the detected KEGG pathways, genes with both up-regulated and down-regulated differential
H3K4me3 signals in HD are highlighted in red. #Gene: Statistics of detected genes (left) and
total genes (right) in a pathway. Nested detected pathways: Pathways detected in this analysis
and embedded in other detected pathways.
(XLSX)
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S6 Table. Pathways enriched with differentially expressed genes. In the link to the detected
KEGG pathways, up-regulated and down-regulated genes in HD are highlighted in red. #Gene:
Statistics of detected genes (left) and total genes (right) in a pathway. Nested detected path-
ways: Pathways detected in this analysis and embedded in other detected pathways.
(XLSX)
S7 Table. List of genes enriched in detected pathways.
(XLSX)
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